(NASDAQ: APGE) Apogee Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Apogee Therapeutics's earnings in 2026 is -$274,615,000.On average, 20 Wall Street analysts forecast APGE's earnings for 2026 to be -$346,979,598, with the lowest APGE earnings forecast at -$396,593,346, and the highest APGE earnings forecast at -$299,537,065. On average, 20 Wall Street analysts forecast APGE's earnings for 2027 to be -$416,224,739, with the lowest APGE earnings forecast at -$762,457,983, and the highest APGE earnings forecast at -$337,216,674.
In 2028, APGE is forecast to generate -$513,288,560 in earnings, with the lowest earnings forecast at -$922,781,028 and the highest earnings forecast at -$377,188,121.